A Chinese tariff cut could reduce U.S. medical-device prices while a 20% domestic-product preference still shapes government tender comparisons.
Primary lensTrade policy
Sub-topicPolicy monitoring
Evidence base7 records used
Use casePolicy monitoring
China could lower tariffs on American medical devices without removing the advantage that locally made equipment receives in covered government tenders. For a U.S. exporter, that means a cheaper import quote can still compare unfavorably after China's domestic-product price adjustment. A U.S. device supplier needs to know whether the saving is large enough to change the evaluated offer.
At the September 20 New York briefing, U.S. Trade Representative Jamieson Greer named medical devices as a potential U.S.-side category for the Board of Trade. Teams were still working on the goods, and he described possible separate treatment in future trade actions. His USTR Greer September 20 remarks on Board of Trade product discussions announced neither device eligibility nor an effective tariff cut.
The procurement rule has applied since January 1, 2026. Product origin and the composition of the bid determine who benefits. An American-owned factory in China can qualify, and some mixed packages can receive the preference even when they include imported equipment.
A tariff concession reaches only one part of the bid
USTR's June 5 Board of Trade notice, 91 FR 34269, envisages changes to certain additional tariffs on equal values of non-sensitive goods. It does not establish reciprocal procurement treatment. Greer's latest comments give exporters a reason to examine device opportunities, but no basis yet for entering a lower Chinese duty rate as an assured saving.
If relief follows, a distributor could use the lower import cost to reduce its tender quote. That result depends on the operative tariff terms and the distributor's pricing. Freight, other taxes, distribution costs and margin do not disappear with the additional duty.
The definition of non-sensitive goods remains important, as Traverse's earlier analysis of the Board's product test explains. For a device included in the relief list, however, the tender comparison would still need its own analysis.
Consider two hypothetical offers for a single-product purchase, with prices expressed as an index. Assume imported products are permitted, the domestic offer qualifies, and no other price adjustment applies.
Offer
Quoted price
Price used for evaluation
Contract price if awarded
Qualifying domestic device
100
80
100
Imported device without the preference
90
90
90
The imported offer costs less to buy but has the higher evaluated price. Technical requirements and other scoring criteria still affect the award. Nor does the example assign an actual tariff rate or predict how much a concession would reduce a quote.
A tariff percentage and a procurement deduction therefore cannot simply be subtracted from each other. The duty applies to the relevant customs value. The evaluation adjustment applies to the procurement offer. An exporter needs the revised delivered quote before testing whether relief changes its competitive position.
This rule also has a defined market boundary. MOF's interpretation describes government procurement by covered bodies using fiscal funds for purchases within the centralized catalogue or above the applicable thresholds. It should not be applied automatically to every hospital purchase or private Chinese customer.
The registered model matters more than the owner's nationality
Notice 34 requires equal treatment of state-owned, private and foreign-invested enterprises whose products qualify. A U.S. company can therefore have a China-produced model receiving domestic treatment alongside an imported model with a different tender position. Treating every product of an American brand as an import would misread the rule.
For registered medical devices, the production inquiry has a specific documentary starting point. The MOF and MIIT implementation opinion on Public Notice 34, Cai Ku 30 of 2025, recognizes devices holding a domestic-form registration certificate as produced in China. It does not make any Chinese registration certificate proof of domestic production.
Article 115 of the NMPA Provisions for Medical Device Registration and Filing, Article 115 distinguishes the domestic registration marker, "zhun," from the imported marker, "jin." Article 8 places Class II and III devices under registration. Class I devices use filing. The sales team should match the exact offered model to its applicable record.
Product-specific domestic component and key-process requirements are being developed under Notice 34. Before applicable requirements take effect, qualifying production in China provides the stated basis for domestic treatment. There is no universal component percentage in the notice that the exporter can substitute for checking its product.
A mixed package changes the calculation
The 80 percent rule operates at a different level. Under Notice 34, a supplier whose qualifying domestic products represent at least 80 percent of its total product costs in a multi-product project or package can receive the deduction on the entire product offer.
That provision can matter to an imported device supplied with qualifying domestic equipment. The imported item does not become domestically produced, but its supplier's package may receive the price preference. The test concerns cost, not the proportion of items, sales revenue or the device's own Chinese component content.
The MOF January 21, 2026 answers on Public Notice 34 and domestic-product procurement clarify that the denominator includes all goods and service products offered in the project or package, and require the supplier to commit to meeting the threshold in its submitted bid or response. The exporter and distributor need the actual package composition and supporting cost calculation before assuming this treatment. The same MOF answers explain that other qualifying price preferences can apply alongside this one. The bid model must reflect the adjustments available under the actual tender.
Reprice the tender when the implementing terms arrive
The next useful update is an operative Chinese tariff measure identifying the covered device, rate and effective period. The underlying Board process remains accessible in Traverse's USTR managed-trade Policy Signal. A category mentioned at a briefing is insufficient to change the duty assumption.
Once coverage is known, the exporter can revise the import cost and distributor quote in its China tender price model. Procurement coverage, permission to offer an imported product, model-specific domestic status and any mixed-package preference should remain explicit alongside that quote. Lower costs may improve the offer without changing those conditions.
A subsequent agreement could change the procurement result. Notice 34 expressly recognizes relevant treaty and agreement provisions. A procurement concession in a final agreement would justify changing the evaluation assumption. A tariff concession alone would justify recalculating the import cost and quote.
From reading to review
Run the numbers on your lane.
The duty calculator runs the current stack for any HTS code and origin. A free account opens full tool output, AD/CVD detail, Chapter 98 processing, and available exports.